Azlocillin

Summary

Azlocillin (CHEMBL1537) is an approved small-molecule antibacterial drug (ATC J01CA09); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA09
• Indications: 1 condition
• Chemistry: 461.5 Da · C20H23N5O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1537
Name	Azlocillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6479523
ChEBI	CHEBI:2956
ATC	J01CA09
Molecular formula	C20H23N5O6S
Molecular weight	461.5
InChIKey	JTWOMNBEOCYFNV-NFFDBFGFSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C

IUPAC name: (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A semisynthetic penicillin having a 6β-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Azlocilina, Azlocillin, Azlocilline, J01CA09, NSC-758227, AZLOCILLIN, AZLOCILLINE, azlocillin

Parent form; salt/anhydrous children: CHEMBL1201041

Patent coverage: 4,340 distinct patent families (17,227 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Gastrin/cholecystokinin type B receptor, Glutamate receptor ionotropic, NMDA 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).